<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03756103</url>
  </required_header>
  <id_info>
    <org_study_id>SPH3127-201</org_study_id>
    <nct_id>NCT03756103</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients</brief_title>
  <official_title>To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>R&amp;G Pharma Studies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential
      hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on
      treating mild-moderate essential hypertension patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose finding trial. Totally 120 mild-moderate essential hypertension patients will
      be enrolled. All the patients will be randomized (1:1:1:1) into four groups (SPH3127 50mg,
      SPH3127 100mg, SPH3127 200mg and placebo).

      The trial has three phases: the screening phase, the leading phase and the treating phase.

      The primary endpoints are the changes of DBP and SBP compared to the baseline after 8 weeks
      of treatment.

      All the adverse events are required to be collected for safety analyzing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline in Seated Systolic Blood Pressure (SBP) and Seated Diastolic Blood Pressure (DBP) After 8 Weeks of Treatment.</measure>
    <time_frame>Baseline to 54-58 days</time_frame>
    <description>To compare the changes of SBP and DBP after 8 weeks of treatment between each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Seated SBP and DBP after 2, 4 and 6 Weeks of Treatment.</measure>
    <time_frame>Baseline to 14±2, 28±2 and 42±2 days</time_frame>
    <description>To compare the changes of seated SBP and DBP after 2, 4 and 6 weeks of treatment between each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in 24-hour Ambulatory Blood Pressure after 8 Weeks of Treatment.</measure>
    <time_frame>Baseline to 54-58 days</time_frame>
    <description>To compare the change from baseline in 24-hour ambulatory blood pressure in each group after 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness Rate after 4 and 8 Weeks of Treatment.</measure>
    <time_frame>Baseline to 28±2 and 56±2 days</time_frame>
    <description>To compare the rates that SBP decreased more than 20 mmHg or DBP decreased more than 10 mmHg between each group after 4 and 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension Controlled Rates after 4 and 8 Weeks of Treatment.</measure>
    <time_frame>Baseline to 28±2 and 56±2 days</time_frame>
    <description>To compare the rates that seated SBP &lt; 140 mmHg and DBP &lt; 90 mmHg between each group after 4 and 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Plasma Renin Activity (PRA) Following 2, 4, 6 and 8 Weeks of Treatment.</measure>
    <time_frame>Baseline to 14±2, 28±2,42±2 and 56±2 days</time_frame>
    <description>To compare the changes of plasma renin activity (PRA) in each group after 2, 4, 6 and 8 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension,Essential</condition>
  <arm_group>
    <arm_group_label>SPH3127 tablet Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 tablet Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 tablet Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 tablet Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 tablet Dose 1</intervention_name>
    <description>Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.</description>
    <arm_group_label>SPH3127 tablet Dose 1</arm_group_label>
    <other_name>renion inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 tablet Dose 2</intervention_name>
    <description>Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.</description>
    <arm_group_label>SPH3127 tablet Dose 2</arm_group_label>
    <other_name>renion inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 tablet Dose 3</intervention_name>
    <description>Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.</description>
    <arm_group_label>SPH3127 tablet Dose 3</arm_group_label>
    <other_name>renion inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 tablet Placebo</intervention_name>
    <description>Oral SPH3127 tablet placebo, once daily for 8 weeks.</description>
    <arm_group_label>SPH3127 tablet Placebo</arm_group_label>
    <other_name>renion inhibitor placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female who is 18 - 65 years old.

          2. Subject who is meeting the diagnostic criteria of mild-moderate essential
             hypertension：mean seated Systolic Blood Pressure (SBP) (2~3 times average) ≥ 140 mmHg
             and ≤ 179 mmHg and mean seated Diastolic Blood Pressure (DBP) (2~3 times average)≥ 90
             and ≤ 109 mmHg.

          3. Laboratory testing should:

        （1） GFR* ≥ 60mL/min （2） AST or ALT is less than 2 times upper limit of normal （3）
        Hemoglobin ≥ 90g/L （4） Serum potassium ≥ 3.5mmol/L and ≤ 5.5mmol/L *the conversion formulas
        for GFR* Male：GFR=186×（Scr)^-1.154×(age)^-0.203；
        Female：GFR=186×（Scr)^-1.154×(age)^-0.203×0.742； Serum creatinine(Scr) unit：µmol/L.

        Exclusion Criteria:

          1. Subject who is diagnosed as a secondary hypertension.

          2. Subject who is suspected to be malignant hypertension, hypertensive emergency,
             hypertensive urgencies patients.

          3. Subject who is at risk when the current anti-hypertensive therapy discontinued.

          4. Subject who is suffered by chronic congestive heart failure (NYHA III and IV) or
             myocardial infarction within 6 months. Subject has had or is currently suffered by
             serious heart disease, such as unstable angina, cardiogenic shock, arrhythmia to that
             needs treatment, heart valve disease, hypertrophic cardiomyopathy, rheumatic heart
             disease, etc.

          5. Subject who is suffered by severe cerebrovascular disease or shock within 6 months,
             such as hypertensive encephalopathy, cerebrovascular injury, cerebral hemorrhage,
             transient ischemic attack etc.

          6. Subject who is suffered by severe or malignant retinopathy. The severe lesions is
             defined as retinal hemorrhage, micro aneurysm, cotton wool patches, hard exudate or a
             combination of these symptoms. The malignant lesions defined as the combination of
             severe retinopathy and optic disc edema.

          7. Subject's medication compliance is not suitable for this trial (use of medication is
             ＜80% or ＞120% in the leading phase).

          8. Subject whose work is associated with such condition as work at height, motor driver
             or operating dangerous machine etc.

          9. Subject who is suffered by aorta-arteritis, large aneurysm or aortic dissection,
             severe subclavian artery stenosis in the past.

         10. Subject who had a gastrointestinal surgery history that may significantly alter drug
             absorption, distribution, metabolism and excretion（For example: gastroectomy,
             gastroenteroanastomosis or enterectomy, gastric bypass, gastrointestinal anastomosis,
             gastrointestinal band surgery, etc.).

         11. Subject who have drug allergy history and anaphylactic reaction.

         12. Subject who is lactating, or is planning to pregnant within six months after the
             trial.

         13. Subject whose diabetes is out of controlled. Defined as fasting blood-glucose is &gt; 7.8
             mmol/L or glycosylated hemoglobin is＞7.5%.

         14. Subject who has a history of malignant tumor.

         15. Subject who has a history of mental disorders.

         16. Subject who has abnormal thyroid function examination or abnormal urine protein check
             value in urine routine(Urine protein test result is a &quot;+&quot; is considered abnormal).

         17. Subject who has participated clinical trials within past 3 months (as a subject).

         18. Subject who is planning or in use of other non-antihypertensive drugs which may affect
             blood pressure（for example: Monoamine oxidase inhibitors, anesthetics, tricyclic and
             tetracyclic antidepressants, non-steroidal anti-inflammatory drugs, reproductive oral
             contraceptive pills, thyroid hormones, adrenocortical hormones, etc.).

         19. Subject who is planning or in use of other antihypertensive drugs during the trial.

         20. Subject who is alcohol abuse （adult male/female consume more than 25g of alcohol per
             day: 25g of alcohol is equivalent to 200 mL of yellow rice wine/wine (15 degrees),
             780mL of beer (4 degrees), 62 mL of liquor (50 degrees)） or drug abuse.

         21. Subject that investigators considered to be not suitable for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Chinese</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changsheng Ma, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhigang Qiu, Master</last_name>
    <phone>+86 13436826627</phone>
    <email>qiuzg@sphchina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobing Cui, Master</last_name>
    <phone>+86 021-63730908</phone>
    <phone_ext>3015</phone_ext>
    <email>cuixb@sphchina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changsheng Ma, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Changsheng Ma, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Wang</last_name>
    </contact>
    <investigator>
      <last_name>Fang Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Ling</last_name>
    </contact>
    <investigator>
      <last_name>Liu Ling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaixin Yu</last_name>
    </contact>
    <investigator>
      <last_name>Zaixin Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Chen</last_name>
    </contact>
    <investigator>
      <last_name>Xiaoping Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second People's Hospital of Guangdong Province</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhui Li, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yuhui Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Medical University Affiliated Hospital</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Yue Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiguang Wang</last_name>
    </contact>
    <investigator>
      <last_name>Jiguang Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Huang</last_name>
    </contact>
    <investigator>
      <last_name>Kai Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyun Ruan</last_name>
    </contact>
    <investigator>
      <last_name>Hongyun Ruan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild-moderate essential hypertension</keyword>
  <keyword>SPH3127 tablet</keyword>
  <keyword>renin inhibitor</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

